Background. Thromboxane (TX) A 2 is a pro-thrombotic prostanoid synthesized in activated platelets from arachidonic acid via cyclooxygenase-1 and 2 and TX synthase activities. TXA 2 is unstable (t½: 32 sec) and non-enzymatically converted to the stable, inactive hydration product TXB 2 . TXB 2 in humans undergoes hepatic bio-transformation mainly into 11-dehydro-TXB 2 , excreted and measurable in urines. Low-dose aspirin inhibits by approx. 70-80% urinary excretion of 11-dehydro-TXB 2 and its recovery after aspirin withdrawal reflects platelets lifespan. Urinary 11-dehydro-TXB 2 level is increased in diseases at high cardiovascular risk and could predict cardiovascular events in aspirin-treated patients. Thus, urinary 11-dehydro-TXB 2 reflects in vivo platelets activation and appears a non-invasive, surrogate biomarker of cardiovascular risk and platelet response to antiplatelet drugs. However, this biomarker awaits validation in large prospective trials. A large urine volume (10-8ml in the original method) 1 and the unknown stability of 11-dehydro-TXB 2 in urine after collection are the main methodological difficulties that might lower feasibility and implementation of 11-dehydro-TXB 2 measurement in large clinical trials. Aims. To adapt the original extraction method from 8 to 1ml urine and assess the stability of 11-dehydro-TXB 2 up to 6 days after urine collection in different experimental conditions. Methods. Urines were collected from 8 controls, 14 diabetic or 10 non-diabetic patients. We scaled down the original method for 10-8ml 1 to 4, 2 and then 1ml urine sample. The sensitivity of the 1-ml method was tested in aspirin-treated patients.
